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Abstract 
Breast cancer is the most common cancer in Malta. 
A National Breast Screening Programme (NBSP) was 
introduced in 2009 for women in the 50 to 60 year old 
age group.  
The first 112 patients diagnosed by the NBSP were 
compared to a matched control group of symptomatic 
patients randomly selected from the Breast Clinic, who 
had presented to the clinic with a breast lump. The files 
of all these patients were reviewed retrospectively. 
In the screening group there were 94 patients with 
invasive cancer and 18 patients with ductal carcinoma in 
situ (DCIS) while in the control group there were 114 
patients with invasive cancer and 3 with DCIS. 
In the screening group, 81 (86.2%) patients with 
invasive cancer underwent wide local excision (WLE) 
and 13 (13.8%) underwent mastectomy. In the control 
group 88 (77.2%) patients with invasive cancer 
underwent WLE and 26 (22.8%) had a mastectomy. 
Out of all the patients in the screened group with 
DCIS, 12 (66.7%) underwent WLE and 6 (33.3%) 
underwent mastectomy. In the control group only 3 
patients had DCIS and these were all treated by WLE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The average Nottingham Prognostic Index (NPI) of 
the screening population with invasive cancer is (3.28 
(95% CI)) and is lower than the NPI of the control group 
is (3.74 (95% CI)). 
This study shows that in the screening group there 
is a higher percentage of patients with DCIS when 
compared to the control group. Furthermore, the 
screened group patients with DCIS were more likely to 
undergo mastectomy than those with invasive cancer. 
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Introduction 
The concept of breast screening is to detect the 
disease at an earlier stage with the intention of 
increasing the life expectancy of the cohort of screened 
women.  
The decision for a country to introduce breast 
screening is usually political (UK, EU, Malta) and the 
available evidence is based on Scandinavian trials 
carried out in the 1970s. The evidence for the benefit for 
breast screening has been recently analysed concluding 
that although breast screening will save some women 
from dying from breast cancer, it over diagnoses the 
disease and will submit many women to unnecessary 
surgery and other treatment.1  
The benefits of breast screening have been 
questioned.2-3 Some claim that overall mortality in 
patients screened for breast cancer may be worse than 
those that are not screened. This is because of damage to 
the coronary arteries secondary to unnecessary 
radiotherapy.4 
There have been dramatic advances in surgery and 
adjuvant treatment for breast cancer in the fourty years 
since the Scandinavian trials were carried out. The 
effectiveness of modern treatment may mean that there 
is little benefit from detecting a breast cancer at an 
earlier stage. Breast screening has also led to an increase 
in patients diagnosed with ductal carcinoma in situ 
(DCIS). The clinical course of this condition has not 
been elucidated and as a result, a high proportion still 
undergo mastectomy. Studies in populations who have 
undergone breast screening fail to demonstrate the 
expected decrease in women presenting with late 
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cancers.3 
The National Breast Screening Programme (NBSP) 
was introduced in Malta in October 2009.5 A dedicated 
unit was established at Lascaris, Valletta, and a database 
was established to screen patients between the ages of 50 
and 60 every three years. Opportunistic screening is also 
carried out in the private sector and this is very popular 
due to a strong media campaign by the two breast non-
governmental organisations (NGOs)6 and also the private 
hospitals and clinics.7 
At this stage it is not possible to compare mortality 
in the screened group with the unscreened population 
because of the small numbers and the short follow up 
period. This paper will study surrogates, even though it 
is accepted that they are imprecise indicators of the 
overall benefit of breast screening a population. We have 
studied mastectomy rates, number of patients with 
DCIS, size of tumour and Nottingham Prognostic Index 
(NPI). 
Breast cancer in Malta 
The crude incidence and crude mortality from 
breast cancer in Malta in the years 1995-2011 is plotted 
in graph 1. This shows that there has been a dramatic 
rise in incidence but the number of deaths has remained 
stable.   
When the figures are adjusted to European Age 
Standardised Rates (EASR) the increase in incidence is 
less marked and this implies that crude figures have 
increased partly because of an aging population. The 
decrease in mortality is substantial, as shown in graph 2. 
The third graph charts the age specific crude 
incidence of breast cancer in Malta.  This has remained 
stable in the below 50 year age group. There was a 
marked increase in the 50-60 year age group and it has 
risen dramatically in the above 60 year age group. The 
fourth graph shows that the crude mortality rates 
remained constant in the three age groups studied. 
 
Figure 1: Crude incidence and mortality of breast cancer in Malta 1995-2011 
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Figure 2:  European age standardised rates of incidence and mortality of breast cancer in Malta 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Age-Group Specific Crude Incidence Trends for Female Breast Cancer 
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Graph 4: Age group specific crude mortality for female breast cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Malta there has been a decrease in mean tumour 
size of invasive breast cancers from 28.2mm in 2000 to 
22.9mm in 2010 (p value =0.007).8 The same study also 
showed a decrease in axillary node metastases at 
presentation and an increase in breast conservation 
surgery. This change is attributed to the establishment of 
the breast clinic in 2000 and various programmes to 
increase breast awareness and not solely to the 
introduction of the NBSP.  
 
Method 
Two cohorts of patients were compared in this 
study. The screening group were all the patients who 
were found to have in situ and invasive carcinoma from 
the start of the NBSP (October 2009) until the date of 
this study (October 2012). There were 112 patients in 
this group. 
The control group were patients who were 
diagnosed as having in situ or invasive breast cancer 
outside the NBSP during the same time period. The files 
of all such patients who were operated for in situ or 
invasive breast cancer in this same period were screened 
for age and those in the same age group as the screening 
group were selected. Of these, 117 were randomly 
chosen to form the control group.  
The patient files were retrieved from the Medical 
Records Office at Mater Dei Hospital and the following 
data was compiled: patient’s age, type of cancer (DCIS 
or Invasive), type of surgery (mastectomy or wide local  
 
 
excision (WLE)), and histological details for tumour 
size, grade and NPI.   
The data was analysed as shown in Table 1 showing 
screening group data and control group data. 
 
Statistical Analysis 
The data collected was analysed using Statistical 
Package for the Social Sciences (SPSS).  
The following variables using Pearson Chi-Square 
test were analysed: the numbers of mastectomies and 
WLE done in the screened group and control group, as 
well as, the type of surgery performed (mastectomy and 
WLE) and tumour status (DCIS and Invasive 
carcinoma). 
In order to evaluate the tumour status with the type 
of surgery performed in screened group and control 
group independently, the Pearson Chi-Square and 
Fisher’s Exact test were used respectively. 
The p value of 0.05 was used as the cut-off for 
statistical significance.  
The t-test was used in order to evaluate if age was a 
significant variable between the screened and the control 
group.  
The univariate analysis of variance (UniANOVA) 
was used to analyse the mean NPI between the screened 
group and the control group, corrected for age. The p 
value of 0.05 was used as the cut-off for statistical 
significance.
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Table 1: Screening Group and Control Group Data 
 
  DCIS  (non-invasive) 
Invasive 
(lobular/ductal/infiltrative) 
Screening Group 
WLE 12 81 
Mastectomy 6 13 
 
Control Group 
WLE 3 88 
Mastectomy 0 26 
  DCIS  (non-invasive) 
Invasive 
(lobular/ductal/infiltrative) 
Screening Group 
WLE 12 81 
Mastectomy 6 13 
 
Control Group 
WLE 3 88 
Mastectomy 0 26 
 
Results 
Our unit aims at breast conservation treatment and  
opt for mastectomy if large tumours, small breasts or 
multifocal and multicentric disease is involved.9 
The number of mastectomies in the control group 
was 26/107 (24%) which is higher than the number in 
the screening group which was 19/112 (17%), but these 
did not reach statistical significance according to the 
Pearson Chi- Sqaured Test (p 0.317). 
There were less cases of DCIS in the control group 
(n=3, 2.6%) than in the screening group (n=18, 16.1%) 
using Fisher Exact Test (p<0.001).   
The Nottingham Prognostic Index (NPI) uses the 
size, grade and lymph node status of a tumour to predict 
the prognosis.10 The mean NPI in the control group (3.74 
(95% CI)) was higher than that of the screening group 
which had a mean NPI (3.279 (95% CI)) adjusted for 
age (60.9). 
The average tumour size for the control group was 
20.24mm which was higher than that of the screening 
group which was 18.11mm. 
 
Discussion 
This study shows that in the screened group there 
was a higher percentage of patients with DCIS when 
compared to the control group. The difference in size of 
tumour in both groups did not reach statistical 
significance however the NPI was significantly lower in 
the screened group than in the control group. 
In the screened group, patients with DCIS were 
likely to undergo mastectomy (33.3%) than those with 
invasive cancer (13.8%).  
Ductal carcinoma in situ (DCIS) is an intraepithelial 
neoplastic proliferation of epithelial cells that is 
separated from the breast stroma by an intact layer of 
basement membrane and myoepithelial cells.11  DCIS is  
 
usually detected by screen mammography. Up to 40% of 
these lesions progress to invasive disease if untreated but 
it is not yet possible to accurately predict which DCIS 
will progress to invasive breast cancer.12 
The challenge is to treat DCIS effectively to 
decrease the risk of recurrence with the best possible 
cosmetic outcome. Mammography often underestimates 
the size of the lesion and MRI allows more accurate 
planning of surgery. Also large lesions often have foci of 
unsuspected invasive cancer. Mastectomy, possibly with 
immediate reconstruction, offers the highest possibility 
of clearance of DCIS but the cosmetic appearance can be 
severely compromised. Breast conservation surgery 
requires a balance between the margin of excision and 
oncological risk and cosmetic outcome but it is not 
suitable for large lesions or multicentric disease. 
Studies in other institutions have shown that 
screened patients may be overtreated and this is also 
suggested by the results of this study.4, 13-14 The lower 
NPI in the screened group implies a better prognosis in 
screened patients. However this has to be interpreted 
with caution because of lead time bias and possible 
complications from overtreatment. 
The authors suggest repeating this study when a 
larger number of patients are screened. 
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